Condition category
Musculoskeletal Diseases
Date applied
16/01/2014
Date assigned
16/01/2014
Last edited
08/08/2016
Prospective/Retrospective
Prospectively registered
Overall trial status
Ongoing
Recruitment status
Recruiting

Plain English Summary

Background and study aims
Rheumatoid arthritis is a major health problem that affects one adult in a hundred. Its NHS costs exceed £500 million yearly. The main problem in rheumatoid arthritis is swollen (inflamed) joints. If persistent these cause disability and reduce quality of life. It is accepted that patients with active early rheumatoid arthritis need intensive care. This type of care results in reduction in one third of patients. Such reductions minimise disability and maximise quality of life. However, two thirds of active patients fail to achieve this reduction. Their ongoing grumbling arthritis - neither active nor in remission - means most of them are likely to become very disabled in the fullness of time with current treatment approaches. This study focuses on these patients. It is designed to find out whether intensive care results in more reduction of disease in patients with intermediate disease activity. It will also see whether intensive management reduces disability, enhances quality of life and is acceptable to patients.

Who can participate?
The study will involve men and women aged over 18 years who have a diagnosis of Rheumatoid Arthritis.

What does the study involve?
Participants will be randomly chosen to receive intensive management or standard care. Patients receiving intensive management will have monthly sessions with a specialist nurse/health practitioner, drug treatment will be optimised and treatment support regarding pain management, exercise and adherence will be given. The other group will receive standard care. All participants will be in the trial for 12 months. Patients will be assessed initially and at six and 12 months through self-completed questionnaires and clinical evaluation.

What are the possible benefits and risks of participating?
There may not be any direct benefit to participants taking part in the study; however, their arthritis will be monitored very closely by the research team, and it is hoped that this research will help improve the treatment and management of rheumatoid arthritis for all patients in the future. The risks involved in taking part in the study are small. Patients receiving intensive management are likely to receive more drug therapy. While it is possible that this will result in more side effects, there is little evidence that this will occur. This is because close monitoring and adjustment of treatment is more likely to limit the risk of side effects.

Where is the study run from?
The study will be recruiting through rheumatology departments across England. The study will be run from King's College London (UK).

When is the study starting and how long is it expected to run for?
Recruitment will begin around April 2014. Each participant is expected to be enrolled in the trial for a period of 12 months. The study is due to end in July 2017.

Who is funding the study?
The study is funded by a National Institute for Health Research (NIHR), UK.

Who is the main contact?
Professor David L Scott
d.scott1@nhs.net

Trial website

http://www.titrate.org.uk

Contact information

Type

Scientific

Primary contact

Prof David L Scott

ORCID ID

Contact details

Academic Department of Rheumatology
Weston Education Centre
King's College London
Cutcombe Road
Denmark Hill
London
SE5 9RJ
United Kingdom
-
d.scott1@nhs.net

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

15762

Study information

Scientific title

A pragmatic randomised controlled open trial of the effect of intensive management (IM) compared with standard care (SC) on remission rates at 12 months in rheumatoid arthritis patients with intermediate disease activity

Acronym

TITRATE

Study hypothesis

TITRATE will formally test the hypothesis that patients with established RA who currently have intermediate disease activity (defined as DAS28-ESR 3.2-5.1 with at least 3 active joints) and are currently receiving at least one DMARD, are more likely to achieve remission at 12 months if they receive intensive management than if they continue to have standard care.

Ethics approval

West London Research Ethics Committee, 28/10/2013, ref: 13/LO/1308

Study design

Randomised controlled open interventional multicentre trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not currently available in web format. Please use the contact details below to request a patient information sheet.

Condition

Rheumatoid arthritis

Intervention

The study will compare standard care with intensive management over a period of 12 months.
Intensive management will involve monthly sessions with a trained specialist nurse or health practitioner. A management algorithm will be used to optimise drug treatment and treatment support spanning pain management, exercise and adherence will be given. Drugs will be used within their licensed indications.

The control group will receive standard care according to local and national pathways, which normally involves six-monthly clinical reviews.

Intervention type

Other

Phase

Not Applicable

Drug names

Primary outcome measures

Disease remission at 12 months (final assessment) measured by the Disease Activity Score-28 (DAS28) criterion (DAS28-ESR<2.6)

Secondary outcome measures

1. Alternative assessments of remission: Remission measured by the DAS28-CRP and the Simplified Disease Activity Index (SDAI) (remission defined as SDAI≤3.3) at 12 months; remission assessed by all measures at six months.
2. Assessment of Individual Components of Remission: Tender joint counts (68 joints), swollen joint counts (66
joints), patient global assessments on 100mm visual analogue scales (VAS), physician global assessments on
100mm VAS, C-Reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) at baseline, 6 months and 12 months.
3. Disability: Health Assessment Questionnaire (HAQ) at baseline, 6 months and 12 months.
4. Joint Imaging (Predictor of future disability): Plain X-rays of the hands and feet read by a modified Larsen's score at baseline and 12 months.
5. Quality Of Life: EuroQOL 5 Dimensional score (EQ5D-5L) and patient-rated fatigue scale on 100mm VAS at baseline, six and 12 months.
6. Patient Acceptability: Modified version of the Measuring Actual Patient-led Expectations in Rheumatoid Arthritis (MAPLe-RA) questionnaire at baseline and 12 months, Medication Adherence Rating Scale (MARS) and adverse events at baseline, six and 12 months.
7. Economic Assessments: Modified Client Service Receipt Inventory (CSRI) at baseline, six and 12 months.

Overall trial start date

01/04/2014

Overall trial end date

14/07/2018

Reason abandoned

Eligibility

Participant inclusion criteria

Current inclusion criteria as of 11/06/2015:
1. Diagnosis of Rheumatoid Arthritis (by ACR, 2010 criteria)
2. Have received at least one DMARD for at least six months, and currently receiving at least one DMARD
3. Have intermediate disease activity, defined by:
3.1. DAS28-ESR 3.2-5.1.
3.2. At least three active joints (defined as swollen and/or tender) on 66/68 joint count, to include at least one swollen joint
4. Willing and able to follow an intensive management programme
5. Able and willing to give informed consent

Previous inclusion criteria:
1. Diagnosis of Rheumatoid Arthritis (by ACR, 2010 criteria); duration six months to 10 years
2. Have received at least one DMARD for at least six months, and currently receiving at least one DMARD
3. Have intermediate disease activity, defined by:
3.1. DAS28-ESR 3.2-5.1.
3.2. At least three swollen joints and three tender joints on 66/68 joint count
4. Willing and able to follow an intensive management programme
5. Able and willing to give informed consent

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

398

Participant exclusion criteria

1. Major co-morbidities making intensive treatment inadvisable (e.g. heart failure)
2. Previously failed multiple DMARDs (more than or equal to 5 treatments) or having received biologics
3. Irreversible disability from extensive joint damage (for example, replacement of three or more major joints)
4. Women who are pregnant, breastfeeding or planning to conceive
5. Currently in early RA pathway
6. Current or recent (within the previous 12 weeks) participation in another interventional trial

Recruitment start date

01/04/2014

Recruitment end date

30/06/2017

Locations

Countries of recruitment

United Kingdom

Trial participating centre

King's College London
London
SE5 9RJ
United Kingdom

Trial participating centre

38 participating sites
-
United Kingdom

Sponsor information

Organisation

King's College London (UK)

Sponsor details

Strand
London
WC2R 2LS
United Kingdom

Sponsor type

University/education

Website

Organisation

King's College Hospital NHS Foundation Trust (UK)

Sponsor details

Research & Development
161 Denmark Hill
London
SE5 8EF
United Kingdom

Sponsor type

Hospital/treatment centre

Website

Funders

Funder type

Government

Funder name

National Institute for Health Research (NIHR) (UK) - Programme Grant for Applied Research, Ref: RP-PG-0610-10066

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

08/08/2016: the overall trial end date was changed from 14/07/2017 to 14/07/2018. 11/06/2015: the overall trial end date was changed from 31/03/2017 to 14/07/2017.